Daniel A Morgenstern

Trials

Studies that name Daniel A Morgenstern as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:55 UTC. Open this list on ClinicalTrials.gov

• Ph1
  NCT04500548 · Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

  National Cancer Institute (NCI) · withdrawn · Constitutional Mismatch Repair Deficiency Syndrome, Hematopoietic and Lymphoid Cell Neoplasm, Lynch Syndrome · principal investigator
• Ph1/Ph2
  NCT02992964 · Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers

  The Hospital for Sick Children · terminated · Refractory or Recurrent Hypermutated Malignancies, Biallelic Mismatch Repair Deficiency (bMMRD) Positive Patients · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 11:55 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• Cancer Center Administration
  P30CA015704 · NCI · FRED HUTCHINSON CANCER CENTER · PI WENDY LAW · fiscal years 2018 to 2026
  Named on NCT04500548
• Cancer Immunotherapy Trials Network Central Operations and Statistical Center
  UM1CA154967 · NCI · FRED HUTCHINSON CANCER CENTER · PI NANCY ELLEN DAVIDSON · fiscal years 2019 to 2022
  Named on NCT04500548